Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Melanoma|Bladder Cancer|Triple Negative Breast Cancer (TNBC)
Interventions: DRUG: MK-3475|DRUG: INCB024360
Sponsor: Incyte Corporation
Collaborators: Merck Sharp & Dohme LLC